Skip to content

TEAS Reduces Remifentanil Consumption

Effect of Transcutaneous Electrical Acupoint Stimulation on Remifentanil Consumption and Postoperative Pain in Patients Undergoing Radical Mastectomy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03912688
Acronym
TRIM
Enrollment
153
Registered
2019-04-11
Start date
2015-07-31
Completion date
2015-12-31
Last updated
2019-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, Pain

Brief summary

Transcutaneous electrical acupoint stimulation (TEAS) has been shown to decrease the need of opioids including remifentanil during anaesthesia. However, it is not clear whether combination of two or more acupoints could induce stronger analgesia. Moreover, evidence for the long-term effect of TEAS has been limited. The present study was to compare the short-term and long-term effect on pain of dual-acupoint and single-acupoint TEAS.

Interventions

DEVICEsingle acupoint
DEVICEdual acupoints

Sponsors

Air Force Military Medical University, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Masking description

Interventions were performed by a designated investigator who was not involved in the anaesthesia or the follow-up. The stimulator was placed in an opaque box to blind the surgical team and the anesthesiologists to the group allocation.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* 18 to 65 yrs * body mass index (BMI) of 18 to 30 kg/m2 * elective radical mastectomy under general anaesthesia

Exclusion criteria

* contradictions to TEAS * difficulties in communication * histories of general anaesthesia * drug or alcohol abuse or addiction * cardiac dysfunction or severe hypertension * confirmed hepatic dysfunction and renal impairment * the participants recruited into other clinical trials during last three months

Design outcomes

Primary

MeasureTime frame
consumption of remifentanilfrom start of anesthesia to extubation, on average 2 hours

Secondary

MeasureTime frameDescription
time to extubationfrom end of remifentanil infusion to extubation,approximately 10 minutes on average
respiratory depressionend of the surgery to discharge from postanesthesia care unit,with an average of 30 minutes
nausea and vomitingend of the surgery to discharge from postanesthesia care unit,with an average of 30 minutes
time to recallfrom end of remifentanil infusion to patient response to verbal command,approximately 10 minutes on average
patients' satisfaction scorefrom end of surgery to 24 hours after surgery, totally 24 hourspatients' satisfaction score is assessed by a 0-10mm scale, 0 is no pain, 10 is untolerated pain
incidence of pain at 3m after surgeryfrom discharge from hospital to 3 months after surgery, approximately 3 monthspercentage of patients suffering from pain around the incision
incidence of pain at 6m after surgeryfrom discharge from hospital to 6 months after surgery, approximately 3 monthspercentage of patients suffering from pain around the incision
visual analogue scale of painend of the surgery to discharge from postanesthesia care unit,with an average of 30 minutespain intensity is assessed by a 0-10mm scale, 0 is no pain, 10 is untolerated pain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026